Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

Raj Chovatiya, MD, PhD, MSCI, explains how addressing the most burdensome components of chronic hand eczema can improve ...

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Chronic hand eczema is now considered a “common” skin disease in the United States, according to results from the CHECK study ...

From relentless itching and painful flare-ups to sleepless nights and emotional exhaustion, eczema can take a serious toll on both physical and mental well-being. 1,2 For millions of people, it means ...

A mum has opened up about her daughter’s eczema struggles, saying it was heartbreaking to see her baby’s sheets splattered ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help ...

Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, ...

LEO Pharma Inc., a global leader in medical dermatology, today announced new data from the CHECK (Chronic Hand Eczema epidemiology, Care, and Knowledge) study, advancing the understanding of the ...

Sanofi said robust pharmaceutical launches and increased demand for its blockbuster Dupixent drug drove higher sales and adjusted earnings for the third quarter. The French drugmaker on Friday ...